Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Trabectedin |
Synonyms | |
Therapy Description |
Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trabectedin | Yondelis | ET-743 | Chemotherapy - Alkylating 18 | Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03397186 | Phase II | Trabectedin | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | Withdrawn | USA | 0 |
NCT04383119 | Phase II | Gemcitabine Trabectedin | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (ISG-ARTICLE) | Recruiting | ITA | 0 |
NCT04979442 | Phase III | Trabectedin Milademetan | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) (MANTRA) | Terminated | USA | POL | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 4 |
NCT03838744 | Phase II | Olaparib + Trabectedin Trabectedin | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2) | Active, not recruiting | ITA | 0 |
NCT04305548 | Phase II | Trabectedin | Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma (ISG-MCS) | Recruiting | ITA | 0 |
NCT02359474 | Phase II | Trabectedin | Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin (HyperTET) | Active, not recruiting | DEU | 0 |
NCT06263231 | Phase III | Eribulin Trabectedin Pazopanib INT230-6 | A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3) | Recruiting | USA | 0 |
NCT05432791 | Phase II | Pazopanib Olaparib + Temozolomide Trabectedin | Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working | Active, not recruiting | USA | 1 |
NCT03023124 | Phase II | Trabectedin Dacarbazine + Doxorubicin | Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor (STRADA) | Active, not recruiting | ITA | 0 |
NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
NCT05597917 | Phase III | Trabectedin Trabectedin + tTF-NGR | tTF-NGR Randomized Study - STS (TRABTRAP) | Recruiting | DEU | AUT | 0 |
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |